OncLive | Everolimus Offers Benefit in Papillary Renal Cell Carcinoma OncLive Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma (RCC), offering promising overall survival (OS) results and a tolerable side-effect profile, investigators found in a study presented during the 2013 ... |
